Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518200

— · E

b8c57121-b1ca-584d-8da4-3c83853f17e8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.530
  • G2M_CHECKPOINT+0.460
  • MYC_TARGETS_V2+0.440
  • MTORC1_SIGNALING+0.390
  • CHOLESTEROL_HOMEOSTASIS+0.350
  • MYC_TARGETS_V1+0.340
  • GLYCOLYSIS+0.330
  • UV_RESPONSE_UP+0.330
  • UNFOLDED_PROTEIN_RESPONSE+0.310
  • DNA_REPAIR+0.270

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.350
  • KRAS_SIGNALING_UP-0.310
  • IL2_STAT5_SIGNALING-0.260
  • ANDROGEN_RESPONSE-0.200
  • UV_RESPONSE_DN-0.190
  • BILE_ACID_METABOLISM-0.170
  • COMPLEMENT-0.170
  • FATTY_ACID_METABOLISM-0.150
  • HEME_METABOLISM-0.140
  • IL6_JAK_STAT3_SIGNALING-0.130

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518421
breast-umap@18
—E0.823
2SRR6013551
lung-landscapes@6
—cohortSQ10.815
3TCGA-63-A5MJ-01A-11R-A27Q-07
lung-landscapes@6
—cohortSQ20.815
4TCGA-43-5670-01A-21R-2125-07
lung-landscapes@6
—cohortSQ10.791
5ERR2598071
medullo-epn-umap@date-based
fetalfetal0.778
6TCGA-22-0944-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.778
7MNG1064
mng-umap@100
——0.774
8C3N-02300
lung-landscapes@6
—cohortSQ10.768
9SRR8613740
breast-umap@18
—E0.759
10TCGA-46-6025-01A-11R-1820-07
lung-landscapes@6
—cohortSQ20.758

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.530Inavolisib— uncovered
G2M_CHECKPOINT0.460Inavolisib— uncovered
MYC_TARGETS_V20.440Idelalisib— uncovered
MTORC1_SIGNALING0.390Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.350Remibrutinib— uncovered
MYC_TARGETS_V10.340Inavolisib— uncovered
GLYCOLYSIS0.330Inavolisib— uncovered
UV_RESPONSE_UP0.330Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.310Idelalisib— uncovered
DNA_REPAIR0.270Idelalisib— uncovered
HYPOXIA0.260Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.230Inavolisib— uncovered
APICAL_JUNCTION0.210Inavolisib— uncovered
APICAL_SURFACE0.210Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.210Inavolisib— uncovered
SPERMATOGENESIS0.190Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.180Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.170Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.150Idelalisib— uncovered
MITOTIC_SPINDLE0.130Inavolisib— uncovered